The United States Patent and Trademark Office (USPTO) has granted patent US12583915B2 to Medpacto, Inc. This patent covers methods and compositions for diagnosing cancer, specifically utilizing an antibody or antigen-binding fragment that specifically binds to a BAG2 polypeptide or a fragment thereof. The patent was filed on February 12, 2020, and granted on March 24, 2026, with 16 claims.

This patent grant is primarily an intellectual property matter and does not impose direct regulatory obligations on most entities. However, companies involved in cancer diagnostics, antibody development, or related therapeutic research should be aware of this granted patent. Compliance officers in the pharmaceutical and medical device sectors may need to review their product development pipelines to ensure freedom to operate and avoid potential infringement of this patent. No specific compliance deadlines or penalties are associated with this patent grant itself, beyond the general legal framework governing intellectual property.